^
CANCER:

Clear Cell Renal Cell Carcinoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab
Sensitive
:
A2
PMLive - 6 days - (New A2)
CD27 overexpression
Clear Cell Renal Cell Carcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 3 weeks - (New C3)
No biomarker
Clear Cell Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
avelumab + axitinib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
sunitinib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
pazopanib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
temsirolimus
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
sorafenib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
lenvatinib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
cabozantinib tablet
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
axitinib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
everolimus
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
bevacizumab
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + lenvatinib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
tivozanib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
nivolumab
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
Immunotherapy
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
VEGFR inhibitor
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
Immunotherapy + VEGFR inhibitor
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
Immunotherapy + Tyrosine kinase inhibitor
Sensitive
:
A2
PD-L1 expression
Clear Cell Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive
:
B
PBRM1 mutation
Clear Cell Renal Cell Carcinoma
Immunotherapy
Sensitive
:
B
VHL mutation
Clear Cell Renal Cell Carcinoma
belzutifan
Sensitive
:
C1
PD-L1 expression
Clear Cell Renal Cell Carcinoma
nivolumab + ipilimumab
Sensitive
:
C1
VHL mutation
Clear Cell Renal Cell Carcinoma
PT2385
Sensitive
:
C2
SETD2 mutation
Clear Cell Renal Cell Carcinoma
Immunotherapy
Resistant
:
C3
ERVE-4 expression
Clear Cell Renal Cell Carcinoma
nivolumab
Sensitive
:
C3
SYNE1 mutation
Clear Cell Renal Cell Carcinoma
Immunotherapy
Sensitive
:
C3
HMOX1 expression
Clear Cell Renal Cell Carcinoma
sunitinib
Sensitive
:
C3
CDKN2A mutation
Clear Cell Renal Cell Carcinoma
palbociclib
Sensitive
:
C3
HMOX1 expression
Clear Cell Renal Cell Carcinoma
sorafenib
Sensitive
:
C3